Enzyme-replacement therapies are highly effective for most patients with Gaucher's disease but do little for those with the neuronopathic childhood forms of the disease. Now, an Israeli and U.K. team has unlocked the mechanism of nerve destruction in neuronopathic Gaucher's disease and identified receptor-interacting serine-threonine kinase 3 as a new target.